The content is available as a PDF (143.6 KB).
. 2022 Oct 3;21:S287–S288. doi: 10.1016/S1569-1993(22)01200-0
510 Prevalence and clinical impact of respiratory viral infections in the Standardized Treatment of Pulmonary Exacerbations 2 Study
C Thornton
, L Kalikin
, D Sanders
, S McClellan
, W LeBar
, D VanDevanter
, S Heltshe
, L Caverly
, J LiPuma
C Thornton
Find articles by C Thornton
L Kalikin
Find articles by L Kalikin
D Sanders
Find articles by D Sanders
S McClellan
Find articles by S McClellan
W LeBar
Find articles by W LeBar
D VanDevanter
Find articles by D VanDevanter
S Heltshe
Find articles by S Heltshe
L Caverly
Find articles by L Caverly
J LiPuma
Find articles by J LiPuma
Issue date 2022 Oct.
Copyright © 2022 European Cystic Fibrosis Society. All rights reserved. Published by Elsevier B.V. All rights reserved.
Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
PMCID: PMC9527872